BILIARY TRACT CANCER

This large, late-stage study is testing whether adding a new drug called rilvegostomig to standard chemotherapy helps prevent bile duct or gallbladder cancer from returning after surgery. It involves over 750 patients worldwide who have had their cancer completely removed but rem…

This study is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with advanced bile duct, gallbladder, or related cancers. It aims to see if this combination is safe and can help patients live longer or better control their cancer. The …

This study aimed to test the safety and effectiveness of a two-drug combination (Ezabenlimab and BI 907828) for people with advanced, hard-to-treat cancers that had spread. It was designed for adults with specific types of soft tissue sarcoma, lung, breast, colorectal, or biliary…

This large Phase 3 study compares two different immunotherapy combinations for people with advanced bile duct cancer that cannot be removed by surgery. Researchers are testing whether a new drug called AK112 works better than the established drug durvalumab when both are given wi…

This study is testing a new combination of two drugs, candonilimab and LM-302, for people with advanced bile duct cancer that has continued to grow despite standard chemotherapy and immunotherapy. The goal is to see if this combination can shrink tumors and control the disease fo…

This study is testing an experimental drug called XmAb20717 for people with advanced bile duct or gallbladder cancer that has worsened after standard chemotherapy. It involves 27 participants who will receive the drug to see if it can shrink tumors or slow cancer growth. The goal…

This small, early-stage study is exploring whether a guided therapy session using psilocybin (the active compound in 'magic mushrooms') can help reduce severe depression, anxiety, and emotional distress in people with advanced pancreatic, bile duct, or other gastrointestinal canc…